Prudent cost management in H1; FY20 goals reinstated
01/08/20 -"As expected, the consumer healthcare segment and the neurosciences franchisee were adversely impacted by the pandemic, though the oncology franchisee provided the much needed resilience. ..."
Pages
52
Language
English
Published on
01/08/20
You may also be interested by these reports :
17/12/25
Since Bayer’s shares have already surged 87% ytd, recovering to their highest levels in the last two years, we do not foresee a material upside ...
12/12/25
Eli Lilly’s Retatrutide grabbed headlines with c.29% weight-loss efficacy in late-stage trials for obese patients who also had knee osteoarthritis. ...
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...